S. Béliard-pharmaceuticals, . Msd, N. Novartis, . Nordisk, . F. Sanofi et al., Aegerion Pharmaceuticals Moulin: Aegerion Pharmaceuticals Document review group F. Boccara: Amgen, Isis (now Ionis) Pharmaceuticals Akcea Therapeutics/Ionis Pharmaceuticals

A. Catapano, Z. Reiner, D. Backer, G. Graham, I. Taskinen et al., ESC/EAS Guidelines for the management of dyslipidaemias, Atherosclerosis, vol.217, issue.1, pp.3-46, 2011.
DOI : 10.1016/j.atherosclerosis.2011.06.028

J. Perk, D. Backer, G. Gohlke, H. Graham, I. Reiner et al., European Guidelines on cardiovascular disease prevention in clinical practice (version 2012), Atherosclerosis, vol.223, issue.1, pp.1-68, 2012.
DOI : 10.1016/j.atherosclerosis.2012.05.007
URL : https://hal.archives-ouvertes.fr/hal-00927636

M. Piepoli, A. Hoes, S. Agewall, C. Albus, C. Brotons et al., Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Eur Heart J, vol.pii, pp.2016-106

N. Stone, J. Robinson, A. Lichtenstein, B. Merz, C. Blum et al., AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines, ACC Circulation, vol.129, issue.25 2, pp.49-73, 2013.

L. , D. Morris, P. Ballantyne, C. Birtcher, K. et al., ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk, J Am Coll Cardiol, vol.2016, p.519

G. Development and G. , Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance, BMJ, vol.349, p.4356, 2014.

M. Farnier, E. Bruckert, C. Boileau, and M. Krempf, Diagnostic et traitement des hypercholest??rol??mies familiales (HF) chez l???adulte??: recommandations de la Nouvelle soci??t?? fran??aise d???ath??roscl??rose (NSFA), La Presse M??dicale, vol.42, issue.6, pp.930-50, 2013.
DOI : 10.1016/j.lpm.2013.01.053

B. Nordestgaard, M. Chapman, S. Humphries, H. Ginsberg, L. Masana et al., Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society, European Heart Journal, vol.97, issue.14, pp.3478-90, 2013.
DOI : 10.1136/hrt.2010.213975

L. Ryden, P. Grant, S. Anker, C. Berne, F. Cosentino et al., ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD, Eur Heart J, vol.34, pp.3035-87, 2013.

B. Nordestgaard, A. Langsted, S. Mora, G. Kolovou, H. Baum et al., European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points ? a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine, Eur Heart J, p.2016

B. Jr and H. , Clinical review: the evolving role of HDL in the treatment of high risk patients with cardiovascular disease, J Clin Endocrinol Metab, vol.96, pp.1246-57, 2011.

V. Ramjee, L. Sperling, and T. Jacobson, Non???High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification, Journal of the American College of Cardiology, vol.58, issue.5, pp.457-63, 2011.
DOI : 10.1016/j.jacc.2011.05.009

B. Nordestgaard and . For-the-european, Lipoprotein(a) as a cardiovascular risk factor: current status, European Heart Journal, vol.198, issue.23, pp.2844-53, 2010.
DOI : 10.1016/j.atherosclerosis.2008.02.009
URL : https://hal.archives-ouvertes.fr/inserm-00578888

T. Shah, J. Casas, J. Cooper, I. Tzoulaki, R. Sofat et al., Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts, International Journal of Epidemiology, vol.297, issue.1, pp.217-248, 2009.
DOI : 10.1001/jama.297.6.611

A. Thompson, P. Gao, L. Orfei, S. Watson, D. Angelantonio et al., Lipoprotein-associated phospholipase A(2) and risk of coronary disease , stroke, and mortality: collaborative analysis of 32 prospective studies, Lancet, vol.375, pp.1536-1580, 2010.

N. Paynter, D. Chasman, G. Paré, J. Buring, N. Cook et al., Association Between a Literature-Based Genetic Risk Score and Cardiovascular Events in Women, JAMA, vol.303, issue.7, pp.631-638, 2010.
DOI : 10.1001/jama.2010.119

H. Tada, O. Melander, J. Louie, J. Tanese, C. Rowland et al., Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history, European Heart Journal, vol.37, issue.6, pp.561-568, 2016.
DOI : 10.1056/NEJMoa0706728

P. Greenland, J. Alpert, G. Beller, E. Benjamin, M. Budoff et al., 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults, Journal of the American College of Cardiology, vol.56, issue.25, pp.50-103, 2010.
DOI : 10.1016/j.jacc.2010.09.001

G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti et al., 2013 ESH/ESC Guidelines for the management of arterial hypertension, Journal of Hypertension, vol.31, issue.7, pp.1281-357, 2013.
DOI : 10.1097/01.hjh.0000431740.32696.cc

M. Kavousi, S. Elias-smale, J. Rutten, M. Leening, R. Vliegenthart et al., Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification, Annals of Internal Medicine, vol.156, issue.6, pp.438-482, 2012.
DOI : 10.7326/0003-4819-156-6-201203200-00006

J. Yeboah, R. Young, R. Mcclelland, J. Delaney, T. Polonsky et al., Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment, Journal of the American College of Cardiology, vol.67, issue.2, pp.139-186, 2016.
DOI : 10.1016/j.jacc.2015.10.058

E. Degoma, R. Dunbar, D. Jacoby, and B. French, Differences in absolute risk of cardiovascular events using risk-refinement tests: A systematic analysis of four cardiovascular risk equations, Atherosclerosis, vol.227, issue.1, pp.172-179, 2013.
DOI : 10.1016/j.atherosclerosis.2012.12.025

Y. Inaba, J. Chen, and S. Bergmann, Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: A meta-analysis, Atherosclerosis, vol.220, issue.1, pp.128-161, 2012.
DOI : 10.1016/j.atherosclerosis.2011.06.044

T. Brott, J. Halperin, S. Abbara, J. Bacharach, J. Barr et al., 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery, Circulation, vol.124, issue.4, pp.489-532, 2011.
DOI : 10.1161/CIR.0b013e31820d8d78

E. Roberts, A. Horne, and S. Martin, Cost-Effectiveness of Coronary Artery Calcium Testing for Coronary Heart and Cardiovascular Disease Risk Prediction to Guide Statin Allocation: The Multi-Ethnic Study of Atherosclerosis (MESA), PLOS ONE, vol.376, issue.21, p.116377, 2015.
DOI : 10.1371/journal.pone.0116377.s004

G. Montalescot, U. Sechtem, and S. Achenbach, 2013 ESC GUIDELINES ON THE MANAGEMENT OF STABLE CORONARY ARTERY DISEASE, Russian Journal of Cardiology, vol.34, issue.7, pp.2949-3003, 2013.
DOI : 10.15829/1560-4071-2014-7-7-79

A. Mente, L. De-koning, H. Shannon, and S. Anand, A Systematic Review of the Evidence Supporting a Causal Link Between Dietary Factors and Coronary Heart Disease, Archives of Internal Medicine, vol.169, issue.7, pp.659-69, 2009.
DOI : 10.1001/archinternmed.2009.38

F. Hu and W. Willett, Optimal Diets for Prevention of Coronary Heart Disease, JAMA, vol.288, issue.20, pp.2569-78, 2002.
DOI : 10.1001/jama.288.20.2569

B. Spring, A. Moller, L. Colangelo, J. Siddique, M. Roehrig et al., Healthy Lifestyle Change and Subclinical Atherosclerosis in Young Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study, Circulation, vol.130, issue.1, pp.10-17, 2014.
DOI : 10.1161/CIRCULATIONAHA.113.005445

R. Estruch, R. E. Salas-salvadó, J. Covas, M. , C. D. Arós et al., Primary Prevention of Cardiovascular Disease with a Mediterranean Diet, New England Journal of Medicine, vol.368, issue.14, pp.1279-990, 2013.
DOI : 10.1056/NEJMoa1200303

A. Astrup, J. Dyerberg, P. Elwood, K. Hermansen, F. Hu et al., The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010?, The American Journal of Clinical Nutrition, vol.67, issue.suppl 1, pp.684-692, 2011.
DOI : 10.1017/S002966510800712X
URL : https://hal.archives-ouvertes.fr/hal-00730164

S. Tarino, P. Sun, Q. Hu, F. Krauss, and R. , Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease, The American Journal of Clinical Nutrition, vol.163, issue.suppl, pp.535-581, 2010.
DOI : 10.1001/archinte.163.6.669

L. Al-khudairy, L. Hartley, C. Clar, N. Flowers, L. Hooper et al., Omega 6 fatty acids for the primary prevention of cardiovascular disease, Cochrane Database of Systematic Reviews, vol.8, issue.11, p.11094, 2015.
DOI : 10.1186/1743-7075-8-36

D. Mozaffarian, M. Katan, A. Ascherio, M. Stampfer, and W. Willett, Trans Fatty Acids and Cardiovascular Disease, New England Journal of Medicine, vol.354, issue.15, pp.1601-1614, 2006.
DOI : 10.1056/NEJMra054035

W. Harris, D. Mozaffarian, E. Rimm, P. Kris-etherton, L. Rudel et al., Omega-6 Fatty Acids and Risk for Cardiovascular Disease: A Science Advisory From the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention, Circulation, vol.119, issue.6, pp.902-909, 2009.
DOI : 10.1161/CIRCULATIONAHA.108.191627

E. Rizos, E. Ntzani, E. Bika, M. Kostapanos, and M. Elisaf, Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events, JAMA, vol.308, issue.10, pp.1024-1057, 2012.
DOI : 10.1001/2012.jama.11374

L. Hartley, M. May, E. Loveman, J. Colquitt, and K. Rees, Dietary fibre for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev, vol.1, p.11472, 2016.

L. Dauchet, P. Amouyel, S. Hercberg, and J. Dallongeville, Fruit and Vegetable Consumption and Risk of Coronary Heart Disease: A Meta-Analysis of Cohort Studies, The Journal of Nutrition, vol.345, issue.10, pp.2588-93, 2006.
DOI : 10.1056/NEJMoa011090

E. Rimm, P. Williams, K. Fosher, M. Criqui, and M. Stampfer, Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors, BMJ, vol.319, issue.7224, pp.1523152-1523160, 1999.
DOI : 10.1136/bmj.319.7224.1523

Y. Zheng, F. Lian, Q. Shi, C. Zhang, Y. Chen et al., Alcohol intake and associated risk of major cardiovascular outcomes in women compared with men: a systematic review and meta-analysis of prospective observational studies, BMC Public Health, vol.34, issue.1, pp.773-782, 2015.
DOI : 10.1016/j.ijcard.2014.04.225

D. Jong, A. Plat, J. Bast, A. Godschalk, R. Basu et al., Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment, European Journal of Clinical Nutrition, vol.134, issue.2, pp.263-73, 2008.
DOI : 10.1038/sj.ejcn.1600559

J. Bard, F. Paillard, and J. Lecerf, Effect of phytosterols/stanols on LDL concentration and other surrogate markers of cardiovascular risk, Diabetes & Metabolism, vol.41, issue.1, pp.69-75, 2015.
DOI : 10.1016/j.diabet.2014.11.006

B. Vergès and F. Fumeron, Potential risks associated with increased plasma plant-sterol levels, Diabetes & Metabolism, vol.41, issue.1, pp.76-81, 2015.
DOI : 10.1016/j.diabet.2014.11.003

H. Berthold, S. Unverdorben, R. Degenhardt, M. Bulitta, and I. Gouni-berthold, Effect of Policosanol on Lipid Levels Among Patients With Hypercholesterolemia or Combined Hyperlipidemia, JAMA, vol.295, issue.19, pp.2262-2271, 2006.
DOI : 10.1001/jama.295.19.2262

R. Hegele, H. Ginsberg, M. Chapman, B. Nordestgaard, J. Kuivenhoven et al., The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management, The Lancet Diabetes & Endocrinology, vol.2, issue.8, pp.655-66, 2014.
DOI : 10.1016/S2213-8587(13)70191-8

E. Stroes, P. Thompson, A. Corsini, G. Vladutiu, F. Raal et al., Statin-associated muscle symptoms: impact on statin therapy???European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management, European Heart Journal, vol.116, issue.17, pp.1012-1034, 2015.
DOI : 10.1161/CIRCULATIONAHA.107.185700

S. Yusuf, J. Bosch, G. Dagenais, J. Zhu, D. Xavier et al., Cholesterol lowering in intermediate-risk persons without cardiovascular disease, N Engl J Med, 2016.

S. Yusuf, E. Lonn, P. Pais, J. Bosch, P. López-jaramillo et al., Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease, New England Journal of Medicine, vol.374, issue.21, 2016.
DOI : 10.1056/NEJMoa1600177

J. Hokanson and M. Austin, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies, Journal of Cardiovascular Risk, vol.3, issue.2, pp.213-222, 1996.
DOI : 10.1097/00043798-199604000-00014

N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham et al., Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies, Circulation, vol.115, issue.4, pp.450-458, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.637793

A. Tirosh, A. Rudich, T. Shochat, D. Tekes-manova, E. Israeli et al., Changes in Triglyceride Levels and Risk for Coronary Heart Disease in Young Men, Annals of Internal Medicine, vol.147, issue.6, pp.377-85, 2007.
DOI : 10.7326/0003-4819-147-6-200709180-00007

M. Chapman, H. Ginsberg, P. Amarenco, F. Andreotti, J. Borén et al., Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, European Heart Journal, vol.82, issue.suppl, pp.1345-61, 2011.
DOI : 10.4065/82.5.551

M. Miller, N. Stone, C. Ballantyne, V. Bittner, M. Criqui et al., Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association, Circulation, vol.123, issue.20, pp.2292-333, 2011.
DOI : 10.1161/CIR.0b013e3182160726

L. Berglund, J. Brunzel, A. Goldberg, I. Goldberg, F. Sacks et al., Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.9, pp.2969-89, 2012.
DOI : 10.1210/jc.2011-3213

Z. Reiner, A. Catapano, D. Backer, G. Graham, I. Taskinen et al., EAS Guidelines for the management of dyslipidemias: the American CollegeTask Force for the management of dyslipidemias of the European Society of Cardiology/American Heart Association Task Force on Practice Guidelines, ESC) and the European Atherosclerosis Society (EAS), pp.49-73, 2011.

S. Rabar, M. Harker, O. Flynn, N. Wierzbicki, and A. , Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance, BMJ, vol.349, issue.jul17 12, p.4356, 2014.
DOI : 10.1136/bmj.g4356

F. Sacks, V. Carey, and J. Fruchart, Combination lipid therapy in type 2 diabetes, N Engl J Med, vol.363, pp.692-696, 2010.

H. Ginsberg, M. Elam, L. Lovato, J. Crouse-3rd, L. Leiter et al., Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, vol.362, pp.1563-74, 2010.

L. Berglund, J. Brunzell, A. Goldberg, I. Goldberg, and A. Stalenhoef, Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis, Best Practice & Research Clinical Endocrinology & Metabolism, vol.28, issue.3, pp.423-460, 2014.
DOI : 10.1016/j.beem.2013.10.002

M. Koren, D. Hunninghake, and A. Investigators, Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The ALLIANCE study, ACC Current Journal Review, vol.14, issue.2, pp.1772-1781, 2004.
DOI : 10.1016/j.accreview.2004.12.117

C. Treatment-trialists-'(-ctt-)-collaboration, C. Baigent, L. Blackwell, J. Emberson, L. Holland et al., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170???000 participants in 26 randomised trials, The Lancet, vol.376, issue.9753, pp.1670-81, 2010.
DOI : 10.1016/S0140-6736(10)61350-5

J. Armitage, L. Bowman, K. Wallendszus, J. Armitage, L. Bowman et al., Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Intensive lowering of LDL-cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial, Lancet, vol.376, pp.1658-69, 2010.

J. De-lemos, M. Blazing, S. Wiviott, E. Lewis, K. Fox et al., Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes, JAMA, vol.292, issue.11, pp.1307-1323, 2004.
DOI : 10.1001/jama.292.11.1307

J. Larosa, S. Grundy, D. Waters, C. Shear, P. Barter et al., Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease, New England Journal of Medicine, vol.352, issue.14, pp.1425-1460, 2005.
DOI : 10.1056/NEJMoa050461

T. Pedersen, N. Cater, O. Faergeman, J. Kastelein, A. Olsson et al., Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial), The American Journal of Cardiology, vol.106, issue.3, pp.354-363, 2010.
DOI : 10.1016/j.amjcard.2010.03.033

C. Cannon, E. Braunwald, C. Mccabe, D. Rader, J. Rouleau et al., Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes, New England Journal of Medicine, vol.350, issue.15, pp.1495-504, 2004.
DOI : 10.1056/NEJMoa040583

C. Cannon, M. Blazing, R. Giugliano, A. Mccagg, J. White et al., Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes, New England Journal of Medicine, vol.372, issue.25, pp.2387-97, 2015.
DOI : 10.1056/NEJMoa1410489
URL : https://hal.archives-ouvertes.fr/hal-01258957

C. Cannon, B. Steinberg, S. Murphy, J. Mega, and E. Braunwald, Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy, Journal of the American College of Cardiology, vol.48, issue.3, pp.438-483, 2006.
DOI : 10.1016/j.jacc.2006.04.070

K. Josan, S. Majumdar, and F. Mcalister, The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials, Canadian Medical Association Journal, vol.178, issue.5, pp.576-84, 2008.
DOI : 10.1503/cmaj.070675

R. Spector and S. Snapinn, Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose, Pharmacology, vol.87, issue.1-2, pp.63-72, 2011.
DOI : 10.1159/000322999

H. Rubins, S. Robins, D. Collins, C. Fye, J. Anderson et al., Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol, New England Journal of Medicine, vol.341, issue.6, pp.410-418, 1999.
DOI : 10.1056/NEJM199908053410604

M. Frick, O. Elo, K. Haapa, O. Heinonen, P. Heinsalmi et al., Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia, New England Journal of Medicine, vol.317, issue.20, pp.1237-1282, 1987.
DOI : 10.1056/NEJM198711123172001

M. Corti, J. Guralnik, M. Salive, T. Harris, L. Ferrucci et al., Clarifying the Direct Relation between Total Cholesterol Levels and Death from Coronary Heart Disease in Older Persons, Annals of Internal Medicine, vol.126, issue.10, pp.753-60, 1997.
DOI : 10.7326/0003-4819-126-10-199705150-00001

S. Rubin, S. Sidney, D. Black, W. Browner, S. Hulley et al., High Blood Cholesterol in Elderly Men and the Excess Risk for Coronary Heart Disease, Annals of Internal Medicine, vol.113, issue.12, pp.916-936, 1990.
DOI : 10.7326/0003-4819-113-12-916

S. Houterman, W. Verschuren, A. Hofman, and J. Witteman, Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study, Journal of Internal Medicine, vol.344, issue.1, pp.25-33, 1999.
DOI : 10.1136/bmj.308.6925.367

L. Simons, Y. Friedlander, J. Mccallum, and J. Simons, Risk factors for coronary heart disease in the prospective Dubbo Study of Australian elderly, Atherosclerosis, vol.117, issue.1, pp.107-125, 1995.
DOI : 10.1016/0021-9150(94)05564-Y

C. Baigent, A. Keech, P. Kearney, L. Blackwell, G. Buck et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, vol.366, pp.1267-78, 2005.

J. Brugts, T. Yetgin, S. Hoeks, A. Gotto, J. Shepherd et al., The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials, BMJ, vol.338, issue.jun30 1, p.2376, 2009.
DOI : 10.1136/bmj.b2376

J. Shepherd, G. Blauw, M. Murphy, E. Bollen, B. Buckley et al., Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, The Lancet, vol.360, issue.9346, pp.1623-1653, 2002.
DOI : 10.1016/S0140-6736(02)11600-X